Dishman Carbogen Amcis Limited — PPTs, 13-08-2025: Investor Presentation

**1. Financial Highlights:**

Net revenue for the quarter rose 35.2% YoY to ₹708.05 Cr. EBITDA surged to ₹140.68 Cr, with margins hitting 19.9%, driving a significant turnaround to profitability (PAT ₹23.41 Cr). CDMO revenue jumped 45.0% YoY to ₹611.25 Cr, boosting overall margins.

**2. Strategic Initiatives & Growth Drivers:**

Strategic initiatives prioritize capacity utilization, targeting small/mid-sized biotech, and geographical expansion. New facilities in Switzerland and France, alongside a CHF 25M co-investment with a Japanese customer, highlight growth drivers.

**3. Business Developments:**

The company has 12 APIs in late-stage Phase III development. Its integrated ADC & Bioconjugation segment is actively securing new client engagements and alliances, indicating pipeline momentum.

**4. Market Position & Competitive Advantage:**

As a leading integrated CDMO with four decades of experience and global approvals, Dishman's cutting-edge High Potency API (HIPO) capabilities, including Asia's largest facility, provide a distinct competitive edge, particularly in Oncology.

**5. Investor Implications:**

The turnaround to profitability, strong revenue growth, and margin expansion suggest positive operational leverage. Strategic investments and focus on high-growth areas like oncology and bioconjugation imply sustained growth potential.